157 related articles for article (PubMed ID: 37078412)
21. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
22. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
[TBL] [Abstract][Full Text] [Related]
23. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
24. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
[TBL] [Abstract][Full Text] [Related]
28. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
29. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
32. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
33. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
[TBL] [Abstract][Full Text] [Related]
34. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
35. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Ravandi F; Borthakur G; Konopleva M; DiNardo CD; Daver N; Pemmaraju N; Kanagal-Shamanna R; Wang X; Huang X; Pierce S; Rausch C; Burger J; Ferrajoli A; Jain N; Popat U; Estrov Z; Verstovsek S; Jabbour E; Garcia-Manero G; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):914-924. PubMed ID: 33901324
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
Daneshbod Y; Kohan L; Taghadosi V; Weinberg OK; Arber DA
Curr Treat Options Oncol; 2019 Feb; 20(2):15. PubMed ID: 30741367
[TBL] [Abstract][Full Text] [Related]
37. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
39. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
[TBL] [Abstract][Full Text] [Related]
40. Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Sun Y; Wu C; Liu C; Shao Z
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]